Global Phesgo Market 2026 strengthening subcutaneous oncology treatments

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Phesgo Market Projected To Become By 2030 Based On Its 2026 Valuation?

The expansion observed during the historic timeframe is attributable to several factors, including an uptick in HER2-positive breast cancer diagnoses, progress made in the creation of monoclonal antibodies, and the proliferation of oncology infusion centers. Additionally, enhanced survival rates resulting from targeted therapy and an increase in approvals for biologic drugs also contributed significantly to this growth.

Anticipated expansion during the forecast period is fueled by the wider implementation of home-based oncology treatment models, increased financial commitments towards combination biologic therapies, the growing preference for subcutaneous drug delivery, breakthroughs in formulation stability technologies, and an escalating need for effective cancer treatment protocols.

Prominent trends anticipated in the forecast period involve the increasing uptake of fixed-dose combination therapies, a growing inclination towards subcutaneous oncology treatments, the broadening availability of HER2-positive breast cancer therapies, an intensified focus on patient convenience and adherence, and improvements in biologic formulation technologies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20347&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Phesgo Market?

The increasing incidence of breast cancer is expected to drive the growth of the Phesgo market going forward. Breast cancer is a malignancy that originates in the cells of the breast, typically in the milk ducts or lobules, and has the capacity to spread to other areas of the body. The rising occurrence of breast cancer is linked to factors such as aging demographics, genetic predispositions, evolving lifestyle habits, environmental exposures, and hormonal influences. Phesgo assists breast cancer patients by providing a convenient, fixed-dose combination of pertuzumab and trastuzumab, two targeted therapies that work together to inhibit the HER2 protein, which is responsible for tumor growth and progression, while also reducing administration time and enhancing the overall treatment experience. For instance, according to the American Cancer Society, a US-based professional organization, the number of new breast cancer cases in the United States increased from 300,590 in 2023 to 313,510 in 2024. Consequently, the rising incidence of breast cancer is a primary driver for the Phesgo market’s growth. The growing demand for personalized medicine is anticipated to propel the growth of the Phesgo market in the future. Personalized medicine involves customizing medical treatment to the specific characteristics of each patient, encompassing their genetic makeup, lifestyle, and environment, to deliver more effective and targeted therapies. The escalating demand for personalized medicine is attributed to advancements in genomics, which enable tailored treatments that improve patient outcomes and minimize adverse effects. Phesgo supports personalized medicine by combining pertuzumab and trastuzumab, two targeted therapies designed to block the HER2 protein in HER2-positive breast cancer patients, into a single, subcutaneous injection that streamlines treatment delivery and aligns with individual patient needs for precision care. As an example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a rise from six in 2022. The newly approved personalized treatments for 2023 also included seven cancer drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is fueling the growth of the Phesgo market.

What Segment Groups Are Identified Within The Phesgo Market?

The phesgo market covered in this report is segmented –

1) By Indication: Early Breast Cancer, Metastatic Breast Cancer

2) By Formulation: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

4) By End User: Hospitals, Oncology Clinics, Home Healthcare

What Trends Are Advancing Progress In The Phesgo Market?

Leading companies in the phesgo market are focusing on introducing innovative therapies, such as monoclonal antibody combination therapy, to enhance treatment efficacy and improve patient outcomes in oncology. Monoclonal antibody combination therapy involves the simultaneous use of two or more monoclonal antibodies to target different aspects of a disease, often leading to improved treatment effectiveness and the ability to overcome potential resistance mechanisms. For instance, in November 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Phesgo combination for Subcutaneous Injection MA, IN. Phesgo is an injectable medication that combines pertuzumab and trastuzumab, two monoclonal antibodies, with hyaluronidase alfa to treat HER2-positive breast cancer and advanced HER2-positive colorectal cancer, offering a convenient subcutaneous administration option instead of intravenous infusion.

Which Companies Hold Significant Positions In The Phesgo Market?

Major companies operating in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.

Read the full phesgo market report here:

https://www.thebusinessresearchcompany.com/report/phesgo-global-market-report

Which Regions Are Projected To Dominate The Phesgo Market In The Coming Years?

North America was the largest region in the phesgo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phesgo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Phesgo Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20347&type=smp

Browse Through More Reports Similar to the Global Phesgo Market 2026, By The Business Research Company

Phosgene Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosgene-global-market-report

Phosphoric Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosphoric-acid-global-market-report

Automated Algo Trading Market Report 2026

https://www.thebusinessresearchcompany.com/report/automated-algo-trading-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795